跳至主要内容
临床试验/ISRCTN71306406
ISRCTN71306406已完成不适用

Prospective, open, pilot study of oral supplementation with lutein in patients having undergone cataract surgery: effect on macular pigment density

Dr. Mann Pharma GmbH, Bausch & Lomb Group (Germany)0 个研究点目标入组 40 人开始时间: 2009年11月25日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Men or women aged over 55 years
  • 2. Having to undergo cataract surgery on one eye (study eye) with extracapsular cataract extraction (ECCE) by phacoemulsification and insertion of a posterior chamber implant
  • 3. Written informed consent

排除标准

  • 1. Body mass index (BMI) greater than or equal to 29 kg/m^2
  • 2. Poor pupillary dilation less than 6 mm with mydriatic drugs
  • 3. Age-related maculopathy or macular degeneration (Age-Related Eye Disease Study [AREDS] class 2, 3 or 4)
  • 4. Diabetic retinopathy
  • 5. History of other progressive disease in the study eye which may complicate the assessment of pigment density
  • 6. Known sensitivity to lutein, vitamin E or vehicules
  • 7. Use of cholesterol-lowering drugs that act as bile acid binders (may interfere with carotenoid absorption) within the last month
  • 8. Concomitant disease or therapy which could interfere with lutein absorption
  • 9. Supplementation with carotenoids within the previous 6 months
  • 10. Drastic change of food and/or food supplements within the last month
  • 11. Involvement in the last 30 days in any investigational drug study

研究者

发起方
Dr. Mann Pharma GmbH, Bausch & Lomb Group (Germany)

相似试验